evinacumab sold brand name evkeeza monoclonal antibody medication treatment homozygous familial hypercholesterolemia common side effects include nasopharyngitis cold influenzalike illness dizziness rhinorrhea runny nose nausea serious hypersensitivity allergic reactions occurred evkeeza clinical evinacumab binds angiopoietinlike protein slows function certain enzymes break fats evinacumab blocks allowing faster break fats lead high evinacumab approved medical use united states february us food drug administration considers firstinclass regeneron invented effectiveness safety evinacumab evaluated doubleblind randomized placebocontrolled trial enrolling participants homozygous familial hypercholesterolemia trial participants received mgkg evinacumab every four weeks participants received participants taking lipidlowering therapies trial conducted united states italy france greece netherlands austria canada australia new zealand ukraine south africa primary measure effectiveness percent change lowdensity lipoprotein ldlc beginning treatment week week participants receiving evinacumab average decrease ldlc participants placebo average us food drug administration fda granted application evinacumab orphan drug breakthrough therapy priority review fda granted approval evkeeza regeneron pharmaceuticals april committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization exceptional circumstances medicinal product evkeeza intended treatment adult adolescent patients aged years older homozygous familial hypercholesterolaemia applicant medicinal product regeneron ireland designated activity company evinacumab approved medical use european union june drug article relating cardiovascular system stub help wikipedia expanding monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikievinacumab